What factors help decide between active surveillance and treatment for intermedi...

These are important questions that many people with intermediate favorable risk prostate cancer face, and the decision-making process can feel overwhelming when weighing monitoring versus active treatment options. Key factors that often influence this choice include age, overall health, personal values about quality of life, anxiety levels about living with untreated cancer, and detailed discussions with the medical team about individual risk factors and prognosis. Connecting with others who have navigated similar decisions can provide valuable perspectives on both the emotional and practical aspects of each pathway.

Dear Jaime A — If none of your readings, measurements, or conditions is any worse than what you've listed, you're sitting in the catbird seat and looking go-o-o-od. Observation should be plenty adequate. Unless you're my age—over 75—or not physically fit, in which case active surveillance would likely be wise. First, though, VERY IMPORTANT CAUTION: Do NOT rush your decision! The medical-industrial complex will press great urgency upon you, and they'll do that with the incessant message of "DO SOMETHING! DO SOMETHING! Well … DON'T! Instead, thoroughly read the patient postings right here on Outcomes4Me. Find and talk to PCa patients in your own circle of friends, neighbors, classmates, coworkers, and such. Go online and read relevant articles from medical journals and results of clinical trials. DO NOT read brochures written as "patient information"—they're all cheerleading for overdiagnosis and overtreatment—as are 95% of all PCa providers, whose primary concern has to be generating billable procedures—not observation or active surveillance. (About me: diagnosed 08/16/23 with Stage 1c, single node, localized PCa, Gleason 4+4, PSA 6.7. Likely overdiagnosed, even more likely overtreated—with 42x EBRT and ADT that I halted at 4 months—a classic case of the "cure" being worse than disease.)